

## Appendix 1 Antipsychotics included in the study


---

ATC Code <sup>a</sup>	
N05AL05	Amisulpride
N05AX12	Aripiprazole
N05AH02	Clozapine
N05AH03	Olanzapine
N05AX08	Risperidone
N05AA01	Chlorpromazine
N05AD08	Droperidol
N05AF01	Flupentixol
N05AB02	Fluphenazine
N05AD01	Haloperidol
N05AH01	Loxapine
N05AG03	Penfluridol
N05AC01	Periciazine
N05AB03	Perphenazine
N05AG02	Pimozide
N05AD05	Pipampérone
N05AC04	Pipotiazine
N05AL01	Sulpiride
N05AL03	Tiapride
N05AF05	Zuclopenthixol

---

<sup>a</sup>ATC: anatomical-therapeutic-chemical

**Appendix 2** Percentage of the cohort members who discontinued their antidepressant treatment according to various definition of early discontinuation (Marseilles, France – n=14518 individuals)



\* within the 6 months following the new antidepressant treatment.

**Appendix 3** Individual and prescriber factors associated with early discontinuation of antidepressant treatment: results of the sensitivity analysis using an interval defining a new antidepressant treatment as 1 year without antidepressant treatment (Marseilles, France – n=5998 individuals; n=1130 prescribers)

	<i>n</i>	Adjusted RR <sup>a</sup>	95% CIs <sup>a</sup>
<b>Individual level</b>			
CMUC coverage <sup>b</sup> (reference: no)	1296	1.11	1.07-1.15
Type of antidepressant treatment (reference: SSRIs <sup>c</sup> )			
<i>Tricyclics and monoamine oxidase inhibitors</i>	477	1.15	1.08-1.20
<i>Miscellaneous other antidepressants</i>	1604	1.04	1.00-1.08
<i>Other cases (≥ 2 types of antidepressant)</i>	24	1.02	.69-1.23
<b>Prescriber level</b>			
Percentage of CMUC-covered patients <sup>b</sup> (%, reference: <5)			
5-23	2948	1.02	.94-1.09
>23	2215	1.09	.98-1.19

<sup>a</sup> Estimated odds ratio were corrected with the method of Zhang and Yu to estimate relative risks (RR) with their 95% confidence intervals (CIs). Results of multilevel logistic regression analyses adjusted for 1) individual level: gender, age number of consultations with private general practitioners and psychiatrists in 2008-2009, chronic somatic illness, chronic psychiatric illness, coprescription of antipsychotics and/or lithium, coprescription of anxiolytics and/or hypnotic; 2) prescriber level: gender, age, annual mean expenditure due to medication prescriptions dispensed/patient in 2008-2009, percentage of patients aged 60 years or more, percentage of patients with chronic illness.

<sup>b</sup> CMUC: Couverture maladie universelle complémentaire (Complementary Universal Health Insurance program covering persons with very low income.

<sup>c</sup> SSRIs: Selective serotonin re-uptake inhibitors.

**Appendix 4** Individual and prescriber factors associated with early discontinuation of antidepressant treatment: results of the sensitivity analysis using two different definitions of early discontinuation of new antidepressant treatment (Marseilles, France – n=14518 individuals; n=1437 prescribers)

	<i>n</i>	Adjusted RR <sup>a</sup>	95% CIs <sup>a</sup>
<b>EARLY DISCONTINUATION = NO ANTIDEPRESSANT REFILL WITHIN THE 6 MONTHS FOLLOWING THE NEW ANTIDEPRESSANT TREATMENT<sup>b</sup></b>			
<b>Individual level</b>			
CMUC coverage <sup>c</sup> (reference: no)	3189	1.13	1.07-1.18
Type of antidepressant treatment (reference: SSRIs <sup>d</sup> )			
<i>Tricyclics and monoamine oxidase inhibitors</i>	1165	1.18	1.10-1.26
<i>Miscellaneous other antidepressants or other cases (≥ 2 types of antidepressant)<sup>e</sup></i>	3831	1.02	.97-1.07
<b>Prescriber level</b>			
Percentage of CMUC-covered patients <sup>c</sup> (%; reference: <5)			
5-23	7164	1.09	1.00-1.18
>23	5348	1.27	1.13-1.41
<b>EARLY DISCONTINUATION = &lt;6 CLAIMS WITHIN THE 6 MONTHS FOLLOWING THE NEW ANTIDEPRESSANT TREATMENT<sup>b</sup></b>			
<b>Individual level</b>			
CMUC coverage <sup>c</sup> (reference: no)	3189	1.07	1.06-1.09
Type of antidepressant treatment (reference: SSRIs <sup>d</sup> )			
<i>Tricyclics and monoamine oxidase inhibitors</i>	1165	1.09	1.07-1.11
<i>Miscellaneous other antidepressants</i>	3755	1.02	1.00-1.03
<i>Other cases (≥ 2 types of antidepressant)</i>	76	.84	.69-.96
<b>Prescriber level</b>			
Percentage of CMUC-covered patients <sup>c</sup> (%; reference: <5)			
5-23	7164	1.01	.97-1.04
>23	5348	1.07	1.02-1.11

<sup>a</sup> Estimated odds ratio were corrected with the method of Zhang and Yu to estimate relative risks (RR) with their 95% confidence intervals (CIs). Results of multilevel logistic regression analyses adjusted for 1) individual level: gender, age number of consultations with private general practitioners and psychiatrists in 2008-2009, chronic somatic illness, chronic psychiatric illness, coprescription of antipsychotics and/or lithium, coprescription of anxiolytics and/or hypnotic; 2) prescriber level: gender, age, annual mean expenditure due to medication prescriptions dispensed/patient in 2008-2009, percentage of patients aged 60 years or more, percentage of patients with chronic illness.

<sup>b</sup> New antidepressant treatment: no antidepressant claim in the 6 months before the index claim.

<sup>c</sup> CMUC: Couverture maladie universelle complémentaire (Complementary Universal Health Insurance program covering persons with very low income.

<sup>d</sup> SSRIs: Selective serotonin re-uptake inhibitors.

<sup>e</sup> The categories "Miscellaneous other antidepressants" and "Other cases ( $\geq 2$  types of antidepressant)" have been merged because no case of discontinuation was found in the latter category.